Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Elevation Oncology, Inc. is an innovative oncology company specializing in the discovery and development of targeted cancer therapies, primarily antibody-drug conjugates (ADCs). Its pipeline includes EO-3021, targeting Claudin 18.2 in gastric and other cancers, and EO-1022, targeting HER3 in solid tumors. The company focuses on addressing unmet medical needs through precision medicine, leveraging proprietary ADC technology, strategic collaborations, and a global development and commercialization approach.
This description was generated via AI from an annual report. Updated about 1 year ago.